Advertisement

Breast Cancer Research and Treatment

, Volume 34, Issue 3, pp 213–219 | Cite as

Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: Immune phenomena or drug toxicity?

  • Gottfried J. Locker
  • Ingrid Simonitsch
  • Robert M. Mader
  • Elisabeth Warlamides
  • Michael F. X. Gnant
  • Raimund Jakesz
  • Hugo Rainer
  • Günther G. Steger
Report

Summary

The application of recombinant colony stimulating factors for chemotherapy induced granulocytopenia is becoming common in clinical oncology. Here we report on localized cutaneous side effects after subcutaneous administration of recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) in 11 patients with breast cancer receiving cytostatic treatment. Seven patients suffering from inflammatory breast cancer received cytostatic chemotherapy with mitoxantrone/cyclophosphamide, whereas four patients suffering from noninflammatory breast cancer received high-dose epirubicin/cyclophosphamide, respectively. rh GM-CSF was applicated subcutaneously in a dose of 5 µg/kg/d for at least ten days. In all patients, sharply demarked, maculous itching and burning erythemas restricted to the injection sites occured after three to four injections of rh GM-CSF. These eruptions cleared within 2 to 3 weeks, but reappeared after reexposure to rh GM-CSF. In contrast to previous sporadic reports, no generalized erythemas were observed. Because of this unexpected and subjectively intolerable side effect, rh GM-CSF administration had to be interrupted in all patients. Histopathological findings revealed skin infiltration with lymphocytes, monocytes/macrophages, neutrophils, and occasionally eosinophils, respectively. Since GM-CSF is known to alter immune functions, it seems likely that the eruptions were at least in part due to local immune reactions.

Key words

GM-CSF cutaneous reactions immune phenomena breast cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ruef C, Coleman DL: Granulocyte-macrophage colonystimulating factor: pleiotropic cytokine with potential clinical usefulness. Rev Infect Dis 12: 41–62, 1990Google Scholar
  2. 2.
    Antman KS, Griffin JD, Elias A, Socinski MA, Ryan L, Cannistra SA, Oette D, Whitley M, Frei E 3d, Schnipper LE: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelo-suppression. N Engl J Med 319: 593–598, 1988Google Scholar
  3. 3.
    Morstyn G, Campell L, Souza LM, Alton NK, Keech J, Green M, Sheridan W, Metcalf D, Fox R: Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1 (8587): 667–672, 1988Google Scholar
  4. 4.
    Weisbart RH, Gasson JC, Golde DW: Colony-stimulating factors and host defense. Ann Int Med 110: 297–303, 1989Google Scholar
  5. 5.
    Gasson JC, Weisbart RH, Kaufman SE, Clark SC, Hewick RM, Wong GG, Golde DW: Purified human GM-colony-stimulating factor: direct action on neutrophils. Science 226: 1339–1342, 1984Google Scholar
  6. 6.
    Tomonaga M, Golde DW, Gasson JC: Biosynthetic (recombinant) human granulocyte-macrophage colony-stimulating factor: effect on normal bone marrow and leukemia cell lines. Blood 67: 31–36, 1986Google Scholar
  7. 7.
    Lopez AF, Williamson J, Gamble JP, Begley CG, Harlan JM, Klebanoff SJ, Waltersdorph A, Wong G, Clark SC, Vadas MA: Recombinant human granulocyte-macrophage colony-stimulating factor stimulatesin vitro mature neutrophil and eosinophil functions, surface receptor expression and survival. J Clin Invest 78: 1220–1228, 1986Google Scholar
  8. 8.
    Weisbart RH, Kwan L, Golde DW, Gasson JC: Human GM-CSF primes neutrophils for enhanced oxidative metabolism in response to the major physiologic chemoattractants. Blood 69: 18–21, 1987Google Scholar
  9. 9.
    Fleischmann J, Golde DW, Weisbart RH, Gasson JC: Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils. Blood 68: 708–711, 1986Google Scholar
  10. 10.
    Arnaout MA, Wang EA, Clark SC, Sieff CA: Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J Clin Invest 78: 597–601, 1986Google Scholar
  11. 11.
    Grabstein KH, Urdal DL, Tushinski RJ, Mochizuki DY, Price VL, Cantrell MA, Gillis S, Comlon PJ: Introduction of macrophage tumorcidal activity by granulocyte-macrophage colony-stimulating factor. Science 232: 506–508, 1986Google Scholar
  12. 12.
    Fabian I, Baldwin GC, Golde DW: Biosynthetic granulocyte-macrophage colony-stimulating factor (GM-CSF) enhances neutrophil cytotoxicity towards human leukemia cells. Leukemia 1: 613–617, 1987Google Scholar
  13. 13.
    Gasson JC: Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 77: 1131–1145, 1991Google Scholar
  14. 14.
    DiPersio JF, Billing P, Williams R, Gasson JC: Human granulocyte-macrophage colony-stimulating factor and other cytokines prime human neutrophils for enhanced arachidonic acid release and leukotriene B4 synthesis. J Immunol 140: 4315–4322, 1988Google Scholar
  15. 15.
    Silberstein DS, Owen WF, Gasson JC, DiPersio JF, Golde DW, Bina JC, Soberman R, Austen KF, David JR: Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol 137: 3290–3294, 1986Google Scholar
  16. 16.
    DiPersio J, Billing P, Kaufmann S, Eghtesady P, Williams RE, Gasson JC: Characterization of the human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor. J Biol Chem 263: 1834–1841, 1988Google Scholar
  17. 17.
    Walker F, Burgess AW: Specific binding of radioiodinated granulocyte-macrophage colony-stimulating factor to hematopoietic cells. EMBO J 4: 933–939, 1985Google Scholar
  18. 18.
    Liberati AM, Cinieri S, Schippa M, Di Clemente F, Filippo S, Grignani F: GM-CSF: clinical trials in non-Hodgkin's lymphoma patients with chemotherapy induced leucopenia. Leukemia 5 (S1): 119–122, 1991Google Scholar
  19. 19.
    Gorin NC, Coiffier B, Hayat M, Fouillard L, Kuentz M, Flesch M, Colombat P, Boivin P, Slavin S, Philip T: Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial. Blood 80: 1149–1157, 1992Google Scholar
  20. 20.
    Kluin-Nelemans JC, Hollander AA, Fibbe WE, Heinhuis RJ, Brand A: Leucocytoclastic vasculitis during GM-CSF therapy. Br J Haematol 73: 419–420, 1989Google Scholar
  21. 21.
    Arning M, Kliche KO, Schneider W: GM-CSF therapy and capillary leak syndrome. Ann Hematol 62: 83, 1991Google Scholar
  22. 22.
    Horn TD, Burke PJ, Karp JE, Hood AF: Intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor causes a cutaneous eruption. Arch Dermatol 127: 49–52, 1991Google Scholar
  23. 23.
    Mehregan DR, Fransway AF, Edmonson JH, Leiferman KM: Cutaneous reactions to granulocyte-macrophage colony-stimulating factor. Arch Dermatol 128: 1055–1059, 1992Google Scholar
  24. 24.
    Steger GG, Locker G, Rainer H, Mader RM, Sieder AE, Gnant MFX, Aberer W, Jakesz R: Cutaneous reactions to GM-CSF in inflammatory breast cancer. N Engl J Med 327: 286, 1992Google Scholar
  25. 25.
    Berdel WE, Dannhauser-Riedl S, Steinhauser G, Winton EF: Various human hematopoietic growth factors (interleukin-3, GM-CSF, G-CSF) stimulate clonal growth of nonhematopoietic tumor cells. Blood 73: 80–83, 1989Google Scholar
  26. 26.
    Dedhar S, Gaboury L, Galloway P, Eaves C: Human granulocyte-macrophage colony-stimulating factor active on a variety of cell types of nonhematopoietic origin. Proc Natl Acad Sci USA 85: 9253–9267, 1988Google Scholar
  27. 27.
    Hoekman K, von Blomberg van der Flier BM, Wagstaff J, Drexhage HA, Pinedo HM: Reversible thyroid dysfunction during treatment with GM-CSF. Lancet 338 (8766): 541–542, 1991Google Scholar
  28. 28.
    Smith PD, Lamerson CL, Wong HL, Wahl LM, Wahl SM: Granulocyte-macrophage colony-stimulating factor stimulates human monocyte accessory cell function. J Immunol 144: 3829–3834, 1990Google Scholar
  29. 29.
    Markowicz S, Engleman EG: Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dentritic cellsin vitro. J Clin Invest 85: 955–961Google Scholar
  30. 30.
    Kupper TS, Lee F, Coleman D, Chodakewitz J, Flood P, Horowitz M: Keratinocyte derived T-cell growth factor (KTGF) is identical to granulocyte macrophage colony stimulating factor (GM-CSF). J Invest Dermatol 91: 185–188, 1988Google Scholar
  31. 31.
    Kupper TS, Lee F, Birchall N, Clark S, Dower S: Interleukin 1 binds to specific receptors on human keratinocytes and induces granulocyte/macrophage colony stimulating factor mRNA and protein: a potential autocrine role for interleukin-1 in epidermis. J Clin Invest 82: 1787–1792, 1988Google Scholar
  32. 32.
    Brown MA, Pierce JH, Watson CJ, Falco J, Ihle JN, Paul WE: B cell stimulatory factor-1/interleukin-4 mRNA is expressed by normal and transformed mast cells. Cell 50: 809–818, 1987Google Scholar
  33. 33.
    Plaut M, Pierce JH, Watson CJ, Hanley-Hyde J, Nordan RP, Paul WE: Mast cell lines produce lymphokines in response to cross-linage of FcεRI or to calcium ionophores. Nature 339: 64–67, 1989Google Scholar
  34. 34.
    Heusser CH, Bews J, Brinkmann V, Delespesse G, Kilchherr E, Ledermann F, Le Gros G, Wagner K: New concepts of IgE regulation. Int Arch Allergy Appl Immunol 94: 87–90, 1991Google Scholar
  35. 35.
    Horn TD, Redd JV, Karp JE, Beschorner WE, Burke PJ, Hood AF: Cutaneous eruptions of lymphocyte recovery. Arch Dermatol 125: 1512–1527, 1989Google Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • Gottfried J. Locker
    • 3
  • Ingrid Simonitsch
    • 1
    • 3
  • Robert M. Mader
    • 3
  • Elisabeth Warlamides
    • 3
  • Michael F. X. Gnant
    • 2
    • 3
  • Raimund Jakesz
    • 2
    • 3
  • Hugo Rainer
    • 3
  • Günther G. Steger
    • 3
  1. 1.Institute of Clinical PathologyUniversity of ViennaViennaAustria
  2. 2.Department of SurgeryUniversity of ViennaViennaAustria
  3. 3.Department of Internal Medicine I, Division of OncologyUniversity of ViennaViennaAustria

Personalised recommendations